Xenon Pharmaceuticals Inc. $XENE Stock Sold by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. decreased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 57.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 247,765 shares of the biopharmaceutical company’s stock after selling 327,979 shares during the quarter. Nan Fung Trinity HK Ltd. owned about 0.26% of Xenon Pharmaceuticals worth $9,214,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in shares of Xenon Pharmaceuticals in the second quarter valued at $454,057,000. Jupiter Topco LLC purchased a new stake in Xenon Pharmaceuticals during the 2nd quarter worth about $252,673,000. Janus Henderson Group PLC lifted its holdings in Xenon Pharmaceuticals by 2.3% during the 1st quarter. Janus Henderson Group PLC now owns 4,175,982 shares of the biopharmaceutical company’s stock worth $242,858,000 after purchasing an additional 91,948 shares in the last quarter. Affinity Asset Advisors LLC lifted its holdings in Xenon Pharmaceuticals by 34.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,675,000 shares of the biopharmaceutical company’s stock worth $97,401,000 after purchasing an additional 425,000 shares in the last quarter. Finally, Jennison Associates LLC boosted its stake in Xenon Pharmaceuticals by 2.1% in the 1st quarter. Jennison Associates LLC now owns 1,318,814 shares of the biopharmaceutical company’s stock worth $76,689,000 after purchasing an additional 26,759 shares during the period. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, CFO Thomas Patrick Kelly bought 15,000 shares of the firm’s stock in a transaction on Wednesday, September 30th. The shares were acquired at an average cost of $37.32 per share, for a total transaction of $559,800.00. Following the purchase, the chief financial officer directly owned 15,000 shares of the company’s stock, valued at $559,800. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Christopher Kenney sold 7,068 shares of the firm’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $60.25, for a total value of $425,847.00. Following the completion of the sale, the insider directly owned 2 shares in the company, valued at approximately $120.50. The trade was a 99.97% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.91% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Needham & Company LLC cut their target price on Xenon Pharmaceuticals from $78.00 to $60.00 and set a “buy” rating for the company in a research note on Friday, September 18th. Royal Bank Of Canada decreased their price target on Xenon Pharmaceuticals from $81.00 to $70.00 and set an “outperform” rating on the stock in a research report on Friday, September 18th. Guggenheim began coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, October 6th. They issued a “buy” rating and a $73.00 price target on the stock. Wells Fargo & Company cut their price objective on shares of Xenon Pharmaceuticals from $69.00 to $64.00 and set an “overweight” rating for the company in a research report on Friday, September 18th. Finally, Robert W. Baird cut their price objective on shares of Xenon Pharmaceuticals from $97.00 to $90.00 and set an “outperform” rating for the company in a research report on Friday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $71.31.

Get Our Latest Stock Report on XENE

Xenon Pharmaceuticals Stock Down 2.6%

Xenon Pharmaceuticals stock opened at $40.99 on Friday. Xenon Pharmaceuticals Inc. has a fifty-two week low of $33.38 and a fifty-two week high of $72.66. The firm’s fifty day moving average price is $41.53 and its 200-day moving average price is $52.14.

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.02. On average, sell-side analysts expect that Xenon Pharmaceuticals Inc. will post -4.59 earnings per share for the current year.

More Xenon Pharmaceuticals News

These are some of the XENE news items that stood out recently:

  • Negative Sentiment: HC Wainwright trimmed its EPS forecasts for 2026–2030, including estimates of losses of $4.53 per share in 2026 and $4.90 in 2027. The changes were generally modest, but weaker projected earnings could weigh on sentiment. Xenon Pharmaceuticals analyst estimates
  • Neutral Sentiment: Despite the lower estimates, HC Wainwright reiterated its Buy rating on XENE. The reports provide no new clinical or business developments, so the estimate revisions are the main reported catalyst.

About Xenon Pharmaceuticals

(Free Report)

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological disorders. The company’s research emphasizes ion channels, proteins that help regulate the electrical activity of nerve cells. Its lead program is azetukalner, formerly known as XEN1101, an oral Kv7 potassium-channel opener being developed for seizure disorders, including focal epilepsy. Xenon is also advancing other drug candidates aimed at neurological conditions. Founded in 1996, Xenon is headquartered in Burnaby, British Columbia, and conducts drug development activities in North America.

Featured Stories

Institutional Ownership by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.